Graftable

Executive Summary

Graftable is a San Francisco-based biotechnology company founded in 2021 that develops regenerative therapies to improve healing and reduce scarring in skin and soft tissues following injury, trauma, or surgery. Its technology accelerates wound repair and enhances functional and cosmetic outcomes, with potential applications in demanding cell types such as pancreatic islets. As a preclinical-stage company, Graftable is positioned in the tissue engineering space, addressing a large unmet need in wound healing and regenerative medicine. The company's platform aims to modulate the wound microenvironment to promote regeneration rather than fibrosis. While still early-stage with no disclosed funding or pipeline, the technology holds promise for broad applications in surgical recovery, trauma care, and chronic wounds. Graftable's success will depend on advancing its candidate into preclinical proof-of-concept studies, securing financing, and establishing partnerships for clinical development.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement60% success
• Q4 2026Preclinical Proof-of-Concept Data Release50% success
• Q2 2026Key Scientific Advisory Board Appointment70% success